BDX vs. DXCM, RMD, BSX, BAX, SYK, WST, MCK, ZTS, GILD, and HCA
Should you be buying Becton, Dickinson and Company stock or one of its competitors? The main competitors of Becton, Dickinson and Company include DexCom (DXCM), ResMed (RMD), Boston Scientific (BSX), Baxter International (BAX), Stryker (SYK), West Pharmaceutical Services (WST), McKesson (MCK), Zoetis (ZTS), Gilead Sciences (GILD), and HCA Healthcare (HCA). These companies are all part of the "medical" sector.
Becton, Dickinson and Company (NYSE:BDX) and DexCom (NASDAQ:DXCM) are both large-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, earnings, risk, community ranking, institutional ownership, profitability and dividends.
DexCom has a net margin of 16.82% compared to Becton, Dickinson and Company's net margin of 6.44%. DexCom's return on equity of 31.01% beat Becton, Dickinson and Company's return on equity.
Becton, Dickinson and Company has a beta of 0.43, suggesting that its share price is 57% less volatile than the S&P 500. Comparatively, DexCom has a beta of 1.23, suggesting that its share price is 23% more volatile than the S&P 500.
87.0% of Becton, Dickinson and Company shares are held by institutional investors. Comparatively, 97.8% of DexCom shares are held by institutional investors. 0.3% of Becton, Dickinson and Company shares are held by insiders. Comparatively, 0.4% of DexCom shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
DexCom received 362 more outperform votes than Becton, Dickinson and Company when rated by MarketBeat users. Likewise, 72.00% of users gave DexCom an outperform vote while only 62.25% of users gave Becton, Dickinson and Company an outperform vote.
Becton, Dickinson and Company has higher revenue and earnings than DexCom. Becton, Dickinson and Company is trading at a lower price-to-earnings ratio than DexCom, indicating that it is currently the more affordable of the two stocks.
Becton, Dickinson and Company presently has a consensus price target of $280.00, suggesting a potential upside of 19.76%. DexCom has a consensus price target of $141.67, suggesting a potential upside of 12.54%. Given Becton, Dickinson and Company's higher probable upside, research analysts clearly believe Becton, Dickinson and Company is more favorable than DexCom.
In the previous week, DexCom had 22 more articles in the media than Becton, Dickinson and Company. MarketBeat recorded 40 mentions for DexCom and 18 mentions for Becton, Dickinson and Company. DexCom's average media sentiment score of 0.66 beat Becton, Dickinson and Company's score of 0.63 indicating that DexCom is being referred to more favorably in the news media.
Summary
DexCom beats Becton, Dickinson and Company on 15 of the 19 factors compared between the two stocks.
Get Becton, Dickinson and Company News Delivered to You Automatically
Sign up to receive the latest news and ratings for BDX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BDX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Becton, Dickinson and Company Competitors List
Related Companies and Tools
